Reuters logo
BRIEF-Ionis Pharmaceuticals provides update on IONIS-TTR Rx program
May 26, 2016 / 11:47 AM / a year ago

BRIEF-Ionis Pharmaceuticals provides update on IONIS-TTR Rx program

May 26 (Reuters) - Ionis Pharmaceuticals Inc

* Provides update on IONIS-TTR Rx program

* Currently evaluating IONIS-TTR Rx in an ongoing Phase 3 study, neuro-ttr, in patients with transthyretin familial amyloid polyneuropathy

* GSK not to initiate Phase 3 outcome study, cardio-ttr, which was planned to evaluate IONIS-TTR Rx in patients with ttr amyloid cardiomyopathy

* GSK will consider options for ttr amyloid cardiomyopathy once additional clinical data are available from ongoing studies Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below